The United States Patent and Trademark Office (USPTO) has issued patent US12577309B2, titled 'Anti-CSF1R antibodies, pharmaceutical compositions, and uses.' This patent grants exclusive rights for antibodies targeting human CSF-1R, methods of production, and related pharmaceutical compositions. The assignee is DRAGONBOAT BIOPHARMACEUTICAL (SHANGHAI) CO., LTD., and the patent was granted on March 17, 2026, following an application filed on December 23, 2020.

This patent grant is primarily relevant for intellectual property management within the pharmaceutical and biotechnology sectors. Companies involved in the development or commercialization of CSF1R-targeting therapies should review this patent to ensure freedom to operate and to identify potential licensing opportunities or infringement risks. No immediate compliance actions are required for entities not directly involved with the patented technology, but ongoing monitoring of patent landscapes is advisable for strategic planning.